18Fluorodeoxyglucose pet is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy Journal Article
| Authors: | Schellenberg, D.; Quon, A.; Minn, A. Y.; Graves, E. E.; Kunz, P.; Ford, J. M.; Fisher, G. A.; Goodman, K. A.; Koong, A. C.; Chang, D. T. |
| Article Title: | 18Fluorodeoxyglucose pet is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy |
| Abstract: | Purpose: This study analyzed the prognostic value of positron emission tomography (PET) for locally advanced pancreas cancer patients undergoing stereotactic body radiotherapy (SBRT). Patients and Methods: Fifty-five previously untreated, unresectable pancreas cancer patients received a single fraction of 25-Gy SBRT sequentially with gemcitabine-based chemotherapy. On the preradiation PET-CT, the tumor was contoured and the maximum standardized uptake value (SUVmax) and metabolic tumor burden (MTB) were calculated using an in-house software application. High-SUVmax and low-SUVmax subgroups were created by categorizing patients above or below the median SUVmax. The analysis was repeated to form high-MTB and low-MTB subgroups as well as clinically relevant subgroups with SUVmax values of <5, 5-10, or >10. Multivariate analysis analyzing SUVmax, MTB, age, chemotherapy cycles, and pretreatment carbohydrate antigen (CA)19-9 was performed. Results: For the entire population, median survival was 12.7 months. Median survival was 9.8 vs.15.3 months for the high- and low- SUVmax subgroups (p <0.01). Similarly, median survival was 10.1 vs. 18.0 months for the high MTB and low MTB subgroups (p <0.01). When clinical SUVmax cutoffs were used, median survival was 6.4 months in those with SUVmax >10, 9.5 months with SUVmax 5.0-10.0, and 17.7 months in those with SUVmax <5 (p <0.01). On multivariate analysis, clinical SUVmax was an independent predictor for overall survival (p = 0.03) and progression-free survival (p = 0.03). Conclusion: PET scan parameters can predict for length of survival in locally advanced pancreas cancer patients. Copyright © 2010 Elsevier Inc. |
| Keywords: | survival; adult; cancer chemotherapy; cancer survival; clinical article; aged; aged, 80 and over; disease-free survival; middle aged; retrospective studies; overall survival; mortality; cancer localization; cisplatin; advanced cancer; capecitabine; gemcitabine; cancer patient; cancer radiotherapy; disease free survival; pancreas cancer; radiation dose; pancreatic neoplasms; chemotherapy; positron emission tomography; methodology; radiopharmaceuticals; pancreas; progression free survival; computer assisted tomography; antimetabolites, antineoplastic; tumor volume; radiotherapy dosage; radiotherapy; ca 19-9 antigen; retrospective study; blood; diagnostic agent; computerized tomography; tumors; pancreas tumor; radiosurgery; fluorodeoxyglucose f 18; fluorodeoxyglucose f18; positron-emission tomography; radiopharmaceutical agent; drug derivative; scintiscanning; multivariate analysis; age distribution; locally advanced; stereotactic body radiotherapy; stereotactic body radiation therapy; deoxycytidine; computer program; antineoplastic antimetabolite; multi variate analysis; multivariant analysis; pet; fluorodeoxyglucose; carbohydrates; median survival; pet scan; standardized uptake values; independent predictors; pre-treatment; ca-19-9 antigen; stereotactic radiotherapy; in-house software; drug products |
| Journal Title: | International Journal of Radiation Oncology, Biology, Physics |
| Volume: | 77 |
| Issue: | 5 |
| ISSN: | 0360-3016 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2010-08-01 |
| Start Page: | 1420 |
| End Page: | 1425 |
| Language: | English |
| DOI: | 10.1016/j.ijrobp.2009.06.049 |
| PUBMED: | 20056345 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 3" - "Export Date: 20 April 2011" - "CODEN: IOBPD" - "Source: Scopus" |
